Synergetics USA (SURG) 6.69 $SURG
35.7% Return Seen to Date on SmarTrend Synergetics USA Call (SURG)
Comtex SmarTrend(R) - Mon Nov 30, 4:59PM CST
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 4 months, Synergetics USA has returned 35.70% as of today's recent price of $6.69.
SURG: 6.69 (+0.09)
Synergetics USA Up 35.7% Since SmarTrend Uptrend Call (SURG)
Comtex SmarTrend(R) - Mon Nov 23, 3:41PM CST
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 4 months, Synergetics USA has returned 35.70% as of today's recent price of $6.69.
SURG: 6.69 (+0.09)
Shares of SURG Up 35.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Nov 16, 11:45AM CST
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 4 months, Synergetics USA has returned 35.70% as of today's recent price of $6.69.
SURG: 6.69 (+0.09)
Synergetics USA Shares Up 35.7% Since SmarTrend's Buy Recommendation (SURG)
Comtex SmarTrend(R) - Mon Nov 09, 10:08AM CST
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 3 months, Synergetics USA has returned 35.70% as of today's recent price of $6.69.
SURG: 6.69 (+0.09)
Synergetics USA Has Returned 35.7% Since SmarTrend Recommendation (SURG)
Comtex SmarTrend(R) - Fri Oct 23, 5:32PM CDT
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 3 months, Synergetics USA has returned 35.70% as of today's recent price of $6.69.
SURG: 6.69 (+0.09)
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc.
PR Newswire - Thu Oct 15, 7:45AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant"
today announced the expiration of the tender offer (the "Offer" by a subsidiary of Valeant Pharmaceuticals International ("VPI" to purchase all of the outstanding shares of Synergetics USA, Inc. (NASDAQ: SURG) ("Synergetics", at a price per share of $6.50, net to the holder in cash (less any applicable withholding taxes and without interest), plus one contractual contingent value right ("CVR" per share, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate net to the holder in cash (less any applicable withholding taxes and without interest) upon the achievement of certain specified milestones.
VRX: 23.25 (-0.24), SURG: 6.69 (+0.09), VRX.TO: 30.31 (-0.31)
Uptrend Call Working As Synergetics USA Stock Rises 34.7% (SURG)
Comtex SmarTrend(R) - Fri Oct 09, 9:43AM CDT
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 2 months, Synergetics USA has returned 34.69% as of today's recent price of $6.64.
SURG: 6.69 (+0.09)
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Synergetics USA, Inc.
PR Newswire - Mon Oct 05, 4:00PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR" with respect to the previously announced tender offer by its indirect wholly owned subsidiary, Blue Subsidiary Corp., for all of the outstanding shares of common stock of Synergetics USA, Inc. (NASDAQ: SURG) ("Synergetics" at a price per share of $6.50, net to the holder in cash (less any applicable withholding taxes and without interest), plus one contractual contingent value right per share, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate net to the holder in cash (less any applicable withholding taxes and without interest) was granted early termination, effective October 5, 2015, by the U.S. Federal Trade Commission. The waiting period was scheduled to expire at 11:59 p.m., New York City time on October 7, 2015. The early termination of the HSR waiting period satisfies one of the conditions to consummate the tender offer. The completion of the tender offer remains subject to certain other conditions as described in the Tender Offer Statement on Schedule TO filed by Valeant on September 16, 2015, as amended. Subject to the satisfaction of the other conditions to closing, the transaction is expected to close in the fourth quarter of 2015.
VRX: 23.25 (-0.24), SURG: 6.69 (+0.09), VRX.TO: 30.31 (-0.31)
SYNERGETICS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Synergetics USA, Inc. (SURG) Over the Proposed Sale of the Company to Valeant Pharmaceuticals
ACCESSWIRE - Thu Sep 17, 1:24PM CDT
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synergetics USA, Inc.
SURG: 6.69 (+0.09)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synergetics USA, Inc. And Encourages Investors To Contact The Firm For Additional Information
PR Newswire - Tue Sep 08, 5:32PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synergetics USA, Inc. (NasdaqCM: SURG) ("Synergetics" or the "Company" relating to the proposed buyout of the Company by Valeant Pharmaceuticals International, Inc.
SURG: 6.69 (+0.09)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Synergetics USA, Inc. of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Valeant Pharmaceuticals International, Inc.
BusinessWire - Tue Sep 08, 10:06AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
VRX: 23.25 (-0.24), SURG: 6.69 (+0.09), VRX.TO: 30.31 (-0.31)
35.7% Return Seen to Date on SmarTrend Synergetics USA Call (SURG)
Comtex SmarTrend(R) - Mon Nov 30, 4:59PM CST
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 4 months, Synergetics USA has returned 35.70% as of today's recent price of $6.69.
SURG: 6.69 (+0.09)
Synergetics USA Up 35.7% Since SmarTrend Uptrend Call (SURG)
Comtex SmarTrend(R) - Mon Nov 23, 3:41PM CST
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 4 months, Synergetics USA has returned 35.70% as of today's recent price of $6.69.
SURG: 6.69 (+0.09)
Shares of SURG Up 35.7% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Nov 16, 11:45AM CST
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 4 months, Synergetics USA has returned 35.70% as of today's recent price of $6.69.
SURG: 6.69 (+0.09)
Synergetics USA Shares Up 35.7% Since SmarTrend's Buy Recommendation (SURG)
Comtex SmarTrend(R) - Mon Nov 09, 10:08AM CST
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 3 months, Synergetics USA has returned 35.70% as of today's recent price of $6.69.
SURG: 6.69 (+0.09)
Synergetics USA Has Returned 35.7% Since SmarTrend Recommendation (SURG)
Comtex SmarTrend(R) - Fri Oct 23, 5:32PM CDT
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 3 months, Synergetics USA has returned 35.70% as of today's recent price of $6.69.
SURG: 6.69 (+0.09)
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc.
PR Newswire - Thu Oct 15, 7:45AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant"
today announced the expiration of the tender offer (the "Offer" by a subsidiary of Valeant Pharmaceuticals International ("VPI" to purchase all of the outstanding shares of Synergetics USA, Inc. (NASDAQ: SURG) ("Synergetics", at a price per share of $6.50, net to the holder in cash (less any applicable withholding taxes and without interest), plus one contractual contingent value right ("CVR" per share, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate net to the holder in cash (less any applicable withholding taxes and without interest) upon the achievement of certain specified milestones. VRX: 23.25 (-0.24), SURG: 6.69 (+0.09), VRX.TO: 30.31 (-0.31)
Uptrend Call Working As Synergetics USA Stock Rises 34.7% (SURG)
Comtex SmarTrend(R) - Fri Oct 09, 9:43AM CDT
SmarTrend identified an Uptrend for Synergetics USA (NASDAQ:SURG) on July 31st, 2015 at $4.93. In approximately 2 months, Synergetics USA has returned 34.69% as of today's recent price of $6.64.
SURG: 6.69 (+0.09)
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Synergetics USA, Inc.
PR Newswire - Mon Oct 05, 4:00PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant"
announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR" with respect to the previously announced tender offer by its indirect wholly owned subsidiary, Blue Subsidiary Corp., for all of the outstanding shares of common stock of Synergetics USA, Inc. (NASDAQ: SURG) ("Synergetics" at a price per share of $6.50, net to the holder in cash (less any applicable withholding taxes and without interest), plus one contractual contingent value right per share, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate net to the holder in cash (less any applicable withholding taxes and without interest) was granted early termination, effective October 5, 2015, by the U.S. Federal Trade Commission. The waiting period was scheduled to expire at 11:59 p.m., New York City time on October 7, 2015. The early termination of the HSR waiting period satisfies one of the conditions to consummate the tender offer. The completion of the tender offer remains subject to certain other conditions as described in the Tender Offer Statement on Schedule TO filed by Valeant on September 16, 2015, as amended. Subject to the satisfaction of the other conditions to closing, the transaction is expected to close in the fourth quarter of 2015. VRX: 23.25 (-0.24), SURG: 6.69 (+0.09), VRX.TO: 30.31 (-0.31)
SYNERGETICS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Synergetics USA, Inc. (SURG) Over the Proposed Sale of the Company to Valeant Pharmaceuticals
ACCESSWIRE - Thu Sep 17, 1:24PM CDT
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Synergetics USA, Inc.
SURG: 6.69 (+0.09)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Synergetics USA, Inc. And Encourages Investors To Contact The Firm For Additional Information
PR Newswire - Tue Sep 08, 5:32PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synergetics USA, Inc. (NasdaqCM: SURG) ("Synergetics" or the "Company"
relating to the proposed buyout of the Company by Valeant Pharmaceuticals International, Inc. SURG: 6.69 (+0.09)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Synergetics USA, Inc. of Commencement of an Investigation Concerning the Fairness of the Sale of the Company to Valeant Pharmaceuticals International, Inc.
BusinessWire - Tue Sep 08, 10:06AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
VRX: 23.25 (-0.24), SURG: 6.69 (+0.09), VRX.TO: 30.31 (-0.31)
